Name: Marché mondial des tests pharmacogénétiques en psychiatrie/dépression – Tendances et prévisions du secteur jusqu’en 2031
Brand: Data Bridge Market Research
SKU: 60335
Price: 4800.00 USD
Availability: InStock
Rating: 4.5 (51 reviews)

Marché mondial des tests de pharmacogénétique en psychiatrie/dépression, par type (anxiété, dépression, troubles de l'humeur, troubles bipolaires, troubles de l'alimentation et troubles psychotiques), produit (consommables, instruments, logiciels et services), type de test (séquençage du génome entier et tests basés sur une matrice chromosomique), type de gène (CYP2C19, CYP2C9 et VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT et autres), type de patient (adulte, gériatrique et enfant), utilisateur final (hôpitaux et cliniques, laboratoires de diagnostic, instituts universitaires et de recherche, et autres), canal de distribution (appel d'offres direct, distribution par des tiers, pharmacie hospitalière et autres) - Tendances et prévisions de l'industrie jusqu'en 2031.

Analyse et perspectives du marché des tests pharmacogénétiques en psychiatrie/dépression

Le nombre croissant de patients souffrant de troubles psychiatriques et de dépression devrait stimuler la croissance du marché. La demande croissante de médecine personnalisée et de précision contribue à stimuler la croissance du marché. Le manque d'experts médicaux et génomiques qualifiés et le manque de preuves cliniques solides peuvent entraver la croissance du marché. Cependant, les avancées technologiques croissantes devraient constituer une opportunité de croissance du marché.

Data Bridge Market Research analyse que le marché mondial des tests pharmacogénétiques en psychiatrie/dépression devrait atteindre 2,66 milliards USD d'ici 2031, contre 1,22 milliard USD en 2023, avec un TCAC de 10,4 % au cours de la période de prévision de 2024 à 2031.

Rapport métrique	Détails
Période de prévision	2024 à 2031
Année de base	2023
Années historiques	2022 (personnalisable pour 2016-2021)
Unités quantitatives	Chiffre d'affaires en milliards USD et volume en unités
Segments couverts	Type (anxiété, dépression, troubles de l'humeur, troubles bipolaires, troubles de l'alimentation et troubles psychotiques), produit (consommables, instruments, logiciels et services), type de test (séquençage du génome entier et tests basés sur des matrices chromosomiques), type de gène (CYP2C19, CYP2C9 et VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT et autres), type de patient (adulte, gériatrique et enfant), utilisateur final (hôpital et cliniques, laboratoires de diagnostic, instituts universitaires et de recherche, et autres), canal de distribution (appel d'offres direct, distribution par des tiers, pharmacie hospitalière et autres)
Pays couverts	États-Unis, Canada, Mexique, Allemagne, Royaume-Uni, France, Italie, Pays-Bas, Espagne, Russie, Suisse, Turquie, Pologne, Norvège, Hongrie, Autriche, Irlande, Lituanie, Reste de l'Europe, Chine, Japon, Inde, Corée du Sud, Australie, Singapour, Thaïlande, Indonésie, Malaisie, Philippines, Vietnam, Reste de l'Asie-Pacifique, Brésil, Argentine, Pérou, Reste de l'Amérique du Sud, Arabie saoudite, Émirats arabes unis, Israël, Afrique du Sud, Égypte et Reste du Moyen-Orient et de l'Afrique
Acteurs du marché couverts	Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., Sonic Healthcare Limited, QIAGEN, AB-BIOTICS SA, BiogeniQ Inc., Castle Bioscience Inc., Coriell Life Sciences, Dynamic DNA Laboratories, Eurofins Scientific, Genelex, Genewiz, Genomind Inc., GenXys, HealthSpek, HudsonAlpha, MD Labs, ONEOME LLC et PacBio, entre autres

Définition du marché

Les tests pharmacogénétiques étudient l'interaction entre le médicament et la réponse génétique d'une personne et recherchent la variation génétique responsable de l'influence de l'effet du médicament. Ce test est de plus en plus demandé car de nombreux chercheurs et scientifiques ont identifié l'interaction unique entre les médicaments et les gènes individuels et fournissent des informations précieuses qui peuvent ensuite être utilisées pour développer des médicaments personnalisés.

Tests pharmacogénétiques en psychiatrie/ Dynamique du marché de la dépression

Cette section traite de la compréhension des moteurs, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :

Conducteurs

Augmentation du nombre de personnes souffrant de troubles dépressifs

La dépression est une maladie répandue dans le monde entier qui varie des changements d'humeur normaux. La dépression peut devenir un problème de santé grave, de gravité légère à extrême, qui fait souffrir énormément la personne et peut conduire au suicide dans les cas les plus graves. Bien que plus de 45 antidépresseurs soient disponibles, la réponse sous-optimale pose problème et est considérée comme le résultat d'une variation génétique.

Avec la prévalence croissante de la dépression, la demande de tests pharmacogénétiques augmente également car ils étudient l'effet des variantes génétiques pour fournir un traitement sur mesure, ce qui stimule la croissance du marché.

Croissance du secteur des biotechnologies et hausse des dépenses de santé

Les gens sont de plus en plus conscients de leur santé et sont également attentifs aux soins de santé préventifs. L'accent mis sur les soins de santé gagne en popularité. La connaissance des maladies et des symptômes est essentielle pour le dépistage et la détection précoce des maladies en raison des technologies avancées disponibles dans le système de santé, telles que les tests avancés qui aident les prestataires de soins de santé et conduisent à des taux de survie plus élevés.

Le secteur des biotechnologies en pleine croissance, associé à l’augmentation des dépenses de santé à l’échelle mondiale, devrait stimuler le marché des tests pharmacogénétiques dans les domaines de la psychiatrie et de la dépression. L’accent est mis de plus en plus sur la médecine personnalisée, y compris les tests pharmacogénétiques, à mesure que les entreprises de biotechnologie développent des méthodes et des technologies de test innovantes. Ceci, combiné à l’augmentation des dépenses de santé, indique un investissement croissant dans des solutions de santé avancées qui pourraient améliorer les résultats des patients et réduire les coûts globaux des soins de santé, ce qui stimule la croissance du marché.

Opportunité

Progrès dans les tests génétiques

Le domaine de la santé connaît des avancées technologiques rapides, notamment dans le développement de méthodes nouvelles et sophistiquées pour promouvoir les tests pharmacogénétiques. Ces tests innovants utilisent des méthodes de test génétique avancées pour fournir des résultats précis, permettant aux prestataires de soins de santé d'adapter plus efficacement les schémas thérapeutiques. Cette avancée représente une opportunité importante pour le marché mondial des tests pharmacogénétiques en psychiatrie et dans le domaine de la dépression. À mesure que ces technologies de pointe deviennent plus accessibles et plus perfectionnées, elles ont le potentiel de révolutionner la médecine personnalisée, en offrant aux patients des traitements plus ciblés et plus efficaces pour les problèmes de santé mentale.

Ces tests jouent un rôle crucial dans l'établissement d'un lien significatif entre un médicament et le profil génétique d'un individu. Cette approche personnalisée aide les prestataires de soins de santé à sélectionner les médicaments les plus adaptés aux patients souffrant de troubles dépressifs majeurs et d'autres troubles psychiatriques. En tirant parti des progrès des tests génétiques, les tests pharmacogénétiques peuvent améliorer considérablement les résultats du traitement et améliorer les soins aux patients en psychiatrie et dans le traitement de la dépression, ce qui devrait créer une opportunité de croissance du marché.

Contraintes/Défis

Validation clinique insuffisante

Grâce aux progrès des sciences médicales, de nouvelles méthodes de test sont de plus en plus développées pour proposer des médicaments puissants et efficaces dans le traitement des troubles dépressifs majeurs. Les antidépresseurs et les antipsychotiques utilisés dans les traitements peuvent être inefficaces. Ils peuvent aider à suggérer les médicaments qui peuvent être utilisés pour traiter la maladie en fonction des besoins individuels du patient.

Malgré cet avantage, les tests ne reposent pas sur une base clinique solide pour s'y fier entièrement. Bien que des études menées sur de petites populations aient montré des résultats prometteurs, l'efficacité des tests n'a pas été démontrée sur une population plus large.

Les tests pharmacogénétiques en psychiatrie n'évaluent pas la non-observance des résultats du traitement. Par conséquent, lorsque le taux de non-observance augmente dans la population considérée, la puissance des statistiques diminue, ce qui conduit à un manque de preuves pour prouver l'efficacité des tests.

L'absence de base permettant de s'appuyer entièrement sur ces tests constitue un inconvénient majeur du marché. Les patients préfèrent s'en tenir aux méthodes de test traditionnelles, ce qui freine la croissance du marché.

Inquiétude croissante concernant la confidentialité et la sécurité des données

Les tests pharmacogénétiques, qui analysent la manière dont la constitution génétique d'un individu influence sa réponse aux médicaments, soulèvent d'importantes préoccupations en matière de confidentialité et de sécurité des données, en particulier dans le contexte du partage et du stockage des données à l'échelle mondiale. Les informations génétiques sont intrinsèquement personnelles et peuvent révéler des détails sensibles sur la santé d'un individu, notamment les prédispositions à certaines maladies et les réponses à des médicaments spécifiques. Il existe donc un risque accru que ces informations soient utilisées à mauvais escient ou consultées de manière inappropriée si elles ne sont pas correctement protégées.

Le risque de discrimination génétique est un sujet de préoccupation majeur : les individus pourraient subir des conséquences négatives en matière d’emploi ou d’assurance en raison de leurs informations génétiques. Les violations de données constituent un autre risque important, en particulier dans la mesure où les informations génétiques sont de plus en plus partagées au-delà des frontières à des fins de recherche ou cliniques. Le transfert de données entre des juridictions ayant des réglementations différentes en matière de confidentialité peut encore compliquer les efforts visant à garantir la sécurité des données.

La confidentialité et la sécurité des données constituent des défis majeurs pour la mise en œuvre mondiale des tests pharmacogénétiques sur le marché de la dépression en psychiatrie. En raison de la nature sensible des informations génétiques, il existe un risque potentiel d'utilisation abusive ou d'accès non autorisé aux données des patients qu'ils ont fournies. La nature sensible des données peut donner lieu à plusieurs problèmes, qui devraient remettre en cause la croissance du marché.

Développements récents

En février 2024, Myriad Genetics, Inc., un pionnier des tests génétiques et de la médecine de précision, a acquis certains actifs du laboratoire Precision Genomics (IPG) d'Intermountain Health. Il s'agit notamment du Precise Tumor Test, du Precise Liquid Test et du laboratoire certifié CLIA d'IPG à St. George, dans l'Utah. Cette acquisition permet à Myriad d'améliorer ses offres de profilage tumoral et d'élargir son portefeuille oncologique, qui comprend des options de tests diagnostiques compagnons et de dépistage du cancer héréditaire
En février 2024, QIAGEN a annoncé avoir été récompensée pour ses efforts en matière de développement durable par My Green Lab, une organisation à but non lucratif axée sur la promotion du développement durable dans la recherche scientifique. Cela renforcera la réputation de QIAGEN en matière de développement durable, attirant potentiellement des clients et des partenaires soucieux de l'environnement
En novembre 2023, QIAGEN et DNA Labs International ont collaboré pour résoudre des affaires non résolues vieilles de deux décennies en utilisant le système ForenSeq Kintelligence de QIAGEN pour la généalogie génétique médico-légale, en conjonction avec la base de données GEDmatch PRO. Cela met en évidence l'efficacité et l'adoption croissante de cette approche de l'identification humaine. Cela se traduira par l'efficacité des solutions de généalogie génétique médico-légale de QIAGEN, ce qui stimulera potentiellement leur adoption et leurs ventes sur le marché médico-légal
En juin 2022, Castle Biosciences, Inc, une société qui améliore la santé grâce à des tests innovants qui guident les soins aux patients, a annoncé aujourd'hui avoir signé un accord définitif pour acquérir AltheaDx, Inc. Cette acquisition permettrait de développer potentiellement une franchise de santé mentale, en commençant par un test qui bénéficie actuellement d'un remboursement Medicare pour la dépression
En mai 2022, Coriell Life Sciences a remporté le deuxième prix MedTech Breakthrough Award pour l'innovation génomique, qui ouvre la voie à l'exploitation du pouvoir de la pharmacogénomique pour améliorer les soins de santé. Le programme de sécurité des médicaments Corigen de l'organisation a été nommé « Meilleure solution génomique globale » lors des MedTech Breakthrough Awards 2022. Ce prix donnera aux tests plus de crédibilité auprès des utilisateurs

Portée du marché mondial des tests de pharmacogénétique en psychiatrie/dépression

Le marché mondial des tests pharmacogénétiques en psychiatrie/dépression est segmenté en sept segments notables en fonction du type, du produit, du type de test, du type de gène, du type de patient, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et les différences entre vos marchés cibles.

Taper

Anxiété
Dépression
Troubles de l'humeur
Troubles bipolaires
Troubles de l'alimentation
Troubles psychotiques

Sur la base du type, le marché mondial des tests pharmacogénétiques en psychiatrie/dépression est segmenté en anxiété, dépression, troubles de l’humeur, troubles bipolaires, troubles de l’alimentation et troubles psychotiques.

Produit

Consommables
Instruments
Logiciels et services

Sur la base du produit, le marché mondial des tests pharmacogénétiques en psychiatrie/dépression est segmenté en consommables, instruments, logiciels et services.

Type de test

Séquençage du génome entier
Tests basés sur des matrices chromosomiques

Sur la base du type de test, le marché mondial des tests pharmacogénétiques en psychiatrie/dépression est segmenté en tests basés sur le séquençage du génome entier et sur des tests basés sur des matrices chromosomiques.

Type de gène

CYP2C19
CYP2C9 et VKORC1
CYP2D6
HLA-B
HTR2A/C
HLA-A
CYP3A4
SLC6A4
MTHFR
COMT
Autres

Sur la base du type de gène, le marché mondial des tests pharmacogénétiques en psychiatrie/dépression est segmenté en CYP2C19, CYP2C9 et VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT et autres .

Type de patient

Adulte
Gériatrie
Enfant

Sur la base du type de patient, le marché mondial des tests pharmacogénétiques en psychiatrie/dépression est segmenté en adulte, gériatrique et enfant.

Utilisateur final

Hôpital et cliniques
Laboratoires de diagnostic
Instituts universitaires et de recherche
Autres

Sur la base de l'utilisateur final, le marché mondial des tests pharmacogénétiques en psychiatrie/dépression est segmenté en hôpitaux et cliniques, laboratoires de diagnostic, instituts universitaires et de recherche, et autres.

Canal de distribution

Appel d'offres direct
Distribution par des tiers
Pharmacie de l'hôpital
Autres

Sur la base du canal de distribution, le marché mondial des tests pharmacogénétiques en psychiatrie/dépression est segmenté en appel d'offres direct, distribution par des tiers, pharmacie hospitalière et autres.

Global Pharmacogenetics Testing in Psychiatry/Depression Market Regional Analysis/Insights

The global pharmacogenetics testing in psychiatry/depression market is segmented into seven notable segments based on type, product, test type, gene type, patient type, end user, and distribution channel.

The countries covered in this market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Turkey, Poland, Norway, Hungary, Austria, Ireland, Lithuania, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, and rest of Middle East and Africa.

North America is expected to dominate the global pharmacogenetics testing in psychiatry/depression market as increasing number of population suffering from depressive disorder in the region. The U.S. is expected to dominate the North America region because robust initiatives taken by manufacturers due to genetic variability. China is expected to dominate the Asia-Pacific region due to the growing biotechnology sector along with rising healthcare expenditure. Germany is expected to dominate the Europe region due to increasing interest for personalized and precision medication.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Global Pharmacogenetics Testing in Psychiatry/Depression Market Competitive Landscape and Share Analysis

The global pharmacogenetics testing in psychiatry/depression market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the global pharmacogenetics testing in psychiatry/depression market.

Certains des principaux acteurs opérant sur le marché sont Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., Sonic Healthcare Limited, QIAGEN, AB-BIOTICS SA, BiogeniQ Inc., Castle Bioscience Inc., Coriell Life Sciences, Dynamic DNA Laboratories, Eurofins Scientific, Genelex, Genewiz, Genomind Inc., GenXys, HealthSpek, HudsonAlpha, MD Labs, ONEOME LLC et PacBio, entre autres.

SKU-60335

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

Cliquez sur l'image pour l'agrandir

Tableau de bord d'analyse de données interactif
Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
Accès d'analyste de recherche pour la personnalisation et les requêtes
Analyse de la concurrence avec tableau de bord interactif
Dernières actualités, mises à jour et analyse des tendances
Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence

Demande de démonstration

Table des matières

introduction

OBJECTIVES OF THE STUDY
MARKET DEFINITION
OVERVIEW of Global pharmacogenetic testing in psychiatry/depression market
LIMITATIONs
MARKETS COVERED

MARKET SEGMENTATION

MARKETS COVERED
geographical scope
years considered for the study
currency and pricing
DBMR TRIPOD DATA VALIDATION MODEL
MULTIVARIATE MODELLING
type LIFELINE CURVE
primary interviews with key opinion leaders
DBMR MARKET POSITION GRID
market application coverage grid
vendor share analysis
secondary sourcEs
assumptions

EXECUTIVE SUMMARY
premium insights
REGULATIONS: GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

UNITED STATES

ROLE OF FDA
ROLE OF CDC AND HCFA

EUROPEAN UNION
FRANCE
AUSTRALIA
SOUTH KOREA

market overview

drivers

RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
INITIATIVES TAKEN BY MANUFACTURERS
GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
GROWING MEDICAL TOURISM

RESTRAINTS

LACK OF STRONG CLINICAL EVIDENCE
HIGH COST
LACK OF REIMBURSEMENT

OPPORTUNITIES

TECHNOLOGICAL ADVANCEMENTS
EMERGENCE OF NEW PLAYERS
Untapped market

CHALLENGES

STRINGENT GOVERNMENT REGULATION
SHORTAGE OF SKILLED PERSONNEL

COVID-19 IMPACT ON GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

IMPACT ON PRICE
IMPACT ON DEMAND
IMPACT ON SUPPLY
KEY INITIATIVES BY MARKET PLAYER DURING COVID 19
CONCLUSION:

GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE

overview
WHOLE GENOME SEQUENCING
array-based TESTS

GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES

overview
cyp2c19
CYP2C9 and VKORC1
cyp2d6
HLA-B
htr2a/c
HLA-A
cyp3A4
slc6a4
MTHFR
COMT
others

GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE

overview
PRESCRIPTION DRUGS
Over-the-counter medications
RECREATIONAL DRUGS
VITAMINS/NUTRACEUTICals

GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE

overview
SALIVA
BLOOD

GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY application

overview
DRUG DEVELOPMENT
CLINICAL PRACTICE

GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER

overview
pharmaceutical and biotechnology companies
HEALTHCARE PROVIDERS
research centers and academic institues
others

GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL

overview
RETAIL PHARMACIES
HOSPITAL PHARMACIES
MAIL-ORDER PHARMACIES
DIRECt-to-customer services

GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, by Geography

overview
north america

u.s.
canada
mexico

europe

u.k.
germany
france
italy
spain
netherlands
belgium
russia
switzerland
turkey
rest of europe

Asia-Pacific

JAPAN
cHINA
SOUTH KOREA
INDIA
AUSTRALIA
SINGAPORE
THAILAND
MALAYSIA
indonesia
philipPines
rest of asia-pacific

south america

BRAZIL
argentina
rest of south america

middle east & africa

south africa
saudi arabia
uae
israel
egypt
rest of middle east & africa

Global Pharmacogenetic Testing in psychiatry/depression Market: COMPANY landscape

company share analysis: Global
company share analysis: North America
company share analysis: Europe
company share analysis: Asia-Pacific

swot analysis
company profile

MYRIAD GENETICS, INC.

COMPANY SNAPSHOT
REVENUE ANALYSIS
Company share analysis
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

THERMO FISHER SCIENTIFIC INC.

COMPANY SNAPSHOT
REVENUE ANALYSIS
Company share analysis
PRODUCT PORTFOLIO
RECENT DEVELOPMENT

STADA ARZNEIMITTEL AG

COMPANY SNAPSHOT
REVENUE ANALYSIS
Company share analysis
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

sonic healthcare

COMPANY SNAPSHOT
REVENUE ANALYSIS
Company share analysis
PRODUCT PORTFOLIO
RECENT DEVELOPMENT

Illumina, Inc.

COMPANY SNAPSHOT
REVENUE ANALYSIS
Company share analysis
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

AB-Biotics, S.A.

COMPANY SNAPSHOT
REVENUE ANALYSIS
6.3 PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

ALTHEADX

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENT

biogeniq inc.

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENT

Color

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

cnsdose

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENT

CORIELL LIFE SCIENCES

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

Dynamic DNA Laboratories

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

GENELEX

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENT

genomind, inc.

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

genxys

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

HEALTHSPEK

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENT

HudsonAlpha Health Alliance (A Division of HudsonAlpha)

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENT

luminex corporation

COMPANY SNAPSHOT
REVENUE ANALYSIS
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

MILLENNIUM HEALTH

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

mydna life australia pty ltd.

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENT

oneome

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

OMECARE

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENT

PerkinElmer Inc.

COMPANY SNAPSHOT
REVENUE ANALYSIS
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

R-Biopharm AG

COMPANY SNAPSHOT
PRODUCT PORTFOLIO
RECENT DEVELOPMENTS

questionnaire
related reports

Liste des tableaux

TABLE 1 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, (2021-2028)(USD Million)

TABLE 2 Global Whole Genome Sequencing in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 3 Global Array-Based Tests in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 4 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, (2021-2028)(USD Million)

TABLE 5 Global CYP2C19 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 6 Global CYP2C9 AND VKORC1 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 7 Global CYP2D6 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 8 Global HLA-B in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 9 Global HTR2A/C in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 10 Global HLA-A in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 11 Global CYP3A4 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 12 Global SLC6A4 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 13 Global MTHFR in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 14 Global COMT in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 15 Global Others in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 16 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, (2021-2028)(USD Million)

TABLE 17 Global PRESCRIPTION DRUGS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 18 Global OVER-THE-COUNTER MEDICATIONS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 19 Global RECREATIONAL DRUGS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 20 Global VITAMINS/NUTRACEUTICALS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 21 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, (2021-2028)(USD Million)

TABLE 22 Global Saliva in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 23 Global blood in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 24 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, (2021-2028)(USD Million)

TABLE 25 Global Drug Development in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 26 Global Clinical Practice in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 27 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, (2021-2028)(USD Million)

TABLE 28 Global Pharmaceutical & Biotechnology Companies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 29 Global Healthcare Providers in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 30 Global Research Centres And Academic Institutes in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 31 Global Others in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 32 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, (2021-2028)(USD Million)

TABLE 33 Global Retail Pharmacies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 34 Global Hospital Pharmacies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 35 Global Mail-Order Pharmacies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million))

TABLE 36 Global Direct-To-Customer Services in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 37 Global Pharmacogenetic Testing in psychiatry/depression Market , By Region, 2021-2028 (USD Million)

TABLE 38 north america pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)

TABLE 39 north america pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 40 north america pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 41 north america pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 42 north america pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 43 north america pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 44 north america pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 45 north america pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 46 u.s. pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 47 u.s. pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 48 u.s. pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 49 u.s. pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 50 u.s. pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 51 u.s. pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 52 u.s. pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 53 canada pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 54 canada pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 55 canada pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 56 canada pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 57 canada pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 58 canada pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 59 canada pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 60 mexico pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 61 mexico pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 62 mexico pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 63 mexico pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 64 mexico pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 65 mexico pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 66 mexico pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 67 europe pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)

TABLE 68 europe pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 69 europe pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 70 europe pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 71 europe pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 72 europe pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 73 europe pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 74 europe pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 75 u.k. pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 76 u.k. pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 77 u.k. pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 78 u.k. pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 79 u.k. pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 80 u.k. pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 81 u.k. pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 82 germany pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 83 germany pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 84 germany pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 85 germany pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 86 germany pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 87 germany pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 88 germany pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 89 france pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 90 france pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 91 france pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 92 france pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 93 france pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 94 france pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 95 france pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 96 italy pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 97 italy pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 98 italy pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 99 italy pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 100 italy pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 101 italy pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 102 italy pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 103 spain pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 104 spain pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 105 spain pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 106 spain pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 107 spain pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 108 spain pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 109 spain pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 110 netherlands pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 111 netherlands pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 112 netherlands pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 113 netherlands pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 114 netherlands pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 115 netherlands pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 116 netherlands pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 117 belgium pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 118 belgium pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 119 belgium pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 120 belgium pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 121 belgium pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 122 belgium pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 123 belgium pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 124 russia pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 125 russia pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 126 russia pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 127 russia pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 128 russia pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 129 russia pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 130 russia pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 131 switzerland pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 132 switzerland pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 133 switzerland pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 134 switzerland pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 135 switzerland pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 136 switzerland pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 137 switzerland pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 138 turkey pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 139 turkey pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 140 turkey pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 141 turkey pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 142 turkey pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 143 turkey pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 144 turkey pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 145 rest of europe pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 146 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 147 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 148 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 149 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 150 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 151 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 152 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 153 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 154 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 155 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 156 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 157 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 158 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 159 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 160 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 161 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 162 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 163 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 164 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 165 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 166 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 167 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 168 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 169 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 170 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 171 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 172 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 173 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 174 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 175 India PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 176 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 177 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 178 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 179 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 180 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 181 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 182 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 183 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 184 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 185 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 186 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 187 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 188 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 189 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 190 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 191 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 192 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 193 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 194 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 195 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 196 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 197 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 198 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 199 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 200 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 201 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 202 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 203 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 204 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 205 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 206 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 207 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 208 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 209 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 210 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 211 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 212 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 213 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 214 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 215 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 216 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 217 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 218 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 219 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 220 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 221 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 222 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 223 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 224 Rest of Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 225 south america pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)

TABLE 226 south america pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 227 south america pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 228 south america pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 229 south america pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 230 south america pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 231 south america pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 232 south america pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 233 brazil pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 234 brazil pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 235 brazil pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 236 brazil pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 237 brazil pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 238 brazil pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 239 brazil pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 240 argentina pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 241 argentina pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 242 argentina harmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 243 argentina pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 244 argentina pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 245 argentina pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 246 argentina pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 247 rest of south america pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 248 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)

TABLE 249 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 250 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 251 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 252 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 253 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 254 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 255 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 256 south africa pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 257 south africa pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 258 south africa pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 259 south africa pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 260 south africa pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 261 south africa pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 262 south africa pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 263 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 264 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 265 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 266 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 267 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 268 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 269 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 270 uae pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 271 uae pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 272 uae pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 273 uae pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 274 uae pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 275 uae pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 276 uae pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 277 israel pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 278 israel pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 279 israel pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 280 israel pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 281 israel pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 282 israel pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 283 israel pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 284 egypt pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 285 egypt pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 286 egypt pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 287 egypt pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 288 EGYPT pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 289 egypt pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 290 egypt pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 291 rest of middle east & africa pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

Liste des figures

FIGURE 1 Global PHARMACOGENTIC TESTIG IN PSYCHIATRY/DEPRESSION market: segmentation

FIGURE 2 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: data triangulation

FIGURE 3 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: DROC ANALYSIS

FIGURE 4 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: global vs REGIONAL MARKET ANALYSIS

FIGURE 5 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: COMPANY RESEARCH ANALYSIS

FIGURE 6 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: INTERVIEW DEMOGRAPHICS

FIGURE 7 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL pharmacogenetic testing in psychiatry/depression MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 Global pharmacogenetic testing in psychiatry/depression market: vendor share analysis

FIGURE 10 Global pharmacogenetic testing in psychiatry/depression market: SEGMENTATION

FIGURE 11 initiatives taken by manufacturers is expected to drive THE Global pharmacogenetic testing in psychiatry/depression market IN THE FORECAST PERIOD of 2021 to 2028

FIGURE 12 whole genome sequencing segment is expected to account for the largest share of the Global pharmacogenetic testing in psychiatry/depression market in 2021 & 2028

FIGURE 13 NORTH AMERICA is expected to DOMINATE the gLOBAL pharmacogenetic testing in psychiatry/depression market and ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 asia-pacific is the fastest growing market for pharmacogenetic testing in psychiatry/depression manufacturers in the forecast period of 2021 to 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

FIGURE 16 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028

FIGURE 17 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 18 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 19 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028

FIGURE 21 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028 (USD MILLION)

FIGURE 22 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, CAGR (2021-2028)

FIGURE 23 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, LIFELINE CURVE

FIGURE 24 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028

FIGURE 25 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028 (USD MILLION)

FIGURE 26 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)

FIGURE 27 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 28 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028

FIGURE 29 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028 (USD MILLION)

FIGURE 30 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)

FIGURE 31 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 32 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028

FIGURE 33 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 34 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 35 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 36 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028

FIGURE 37 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 38 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, CAGR (2021-2028)

FIGURE 39 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028

FIGURE 41 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 42 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 43 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 45 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY Region (2020)

FIGURE 46 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY Region (2021 & 2028)

FIGURE 47 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY Region (2020 & 2028)

FIGURE 48 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 49 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 50 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 51 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 52 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 53 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 54 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 55 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 56 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 57 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 58 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 59 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 60 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 61 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 62 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 63 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 64 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 65 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 66 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 67 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 68 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 69 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 70 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 71 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 72 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 73 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 74 Global Pharmacogenetic testing in psychiatry/depression Market: company share 2020 (%)

FIGURE 75 North America pharmacogenetic testing in psychiatry/depression Market: company share 2020 (%)

FIGURE 76 Europe pharmacogenetic testing in psychiatry/depression Market: company share 2020 (%)

FIGURE 77 Asia-Pacific pharmacogenetic testing in psychiatry/DEPRESSION MARKET: company share 2020 (%)

Voir les informations détaillées

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.